Document Detail


Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism.
MedLine Citation:
PMID:  17914676     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The clinical presentations of the patient with pheochromocytoma -- a rare endocrine neoplasm -- include adrenal incidentaloma, hypertensive paroxysms, sustained apparent polygenic hypertension, hypertension in pregnancy, and hypertensive crisis induced by anesthesia. Although when undiagnosed a pheochromocytoma can be lethal, it can usually be cured with surgery. Biochemical documentation with measurements of fractionated metanephrines and catecholamines should precede imaging studies. Abdomen and pelvis computed imaging is usually the first imaging test. Careful preoperative pharmacologic preparation is important for a successful surgical outcome. Adrenal pheochromocytomas can usually be removed laparoscopically, whereas, catecholamine-secreting paragangliomas typically require an open approach. All first degree relatives of pheochromocytoma patients should have biochemical testing. In addition, molecular genetic testing for germline mutations should be considered in most patients with adrenal pheochromocytoma and in all patients with paraganglioma. Primary aldosteronism is a relatively common form of secondary hypertension -- affecting 5 to 10% of all patients with hypertension. A plasma aldosterone concentration (PAC) to plasma renin activity (PRA) ratio should be obtained in patients with hypertension and hypokalemia, resistant hypertension, adrenal incidentaloma and hypertension, onset of hypertension at a young age (e.g., < 20 years of age), severe hypertension (e.g., > or =160 mm Hg systolic or > or =100 mm Hg diastolic), or whenever the clinician is considering other forms of secondary hypertension. The PAC/PRA ratio is a case finding test and a positive result should be confirmed with aldosterone suppression testing with either oral or intravenous sodium loading. The treatment goals for patients with primary aldosteronism are to prevent the morbidity and mortality associated with hypertension, hypokalemia, and cardiovascular damage. Both the subtype of primary aldosteronism and patient preference should dictate the treatment approach.
Authors:
William F Young
Related Documents :
2555106 - Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with...
6625516 - Surgical treatment of primary aldosteronism.
12028606 - Nesiritide: review of clinical pharmacology and role in heart failure management.
11135076 - Prenatal programming of adult hypertension in the rat.
10403606 - Racial differences in aortic stiffness in normotensive and hypertensive adults.
2139406 - Factors influencing humidification in high-frequency jet ventilation.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Reviews in endocrine & metabolic disorders     Volume:  8     ISSN:  1389-9155     ISO Abbreviation:  Rev Endocr Metab Disord     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2008-01-09     Completed Date:  2008-03-17     Revised Date:  2008-08-28    
Medline Journal Info:
Nlm Unique ID:  100940588     Medline TA:  Rev Endocr Metab Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  309-20     Citation Subset:  IM    
Affiliation:
Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA. young.william@mayo.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Glands / metabolism,  pathology*
Aldosterone / blood
Humans
Hyperaldosteronism / blood,  complications*
Hypertension / blood,  etiology*
Models, Biological
Pheochromocytoma / blood,  complications*
Renin / blood
Chemical
Reg. No./Substance:
52-39-1/Aldosterone; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Silicon-based microfilters for whole blood cell separation.
Next Document:  Erectile dysfunction: clinical guidelines (1).